Dr. John C. Henegan
Claim this profileUniversity of Mississippi Medical Center
Studies Cancer
Studies Prostate Cancer
17 reported clinical trials
64 drugs studied
About John C. Henegan
Education:
- Obtained MD from the University of Mississippi School of Medicine in 2007.
- Completed Residency in Internal Medicine at the University of Mississippi Medical Center in 2010.
- Finished Fellowship in Pulmonary and Critical Care Medicine at the same institution in 2013.
Experience:
- Currently serves as an Assistant Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Mississippi Medical Center.
Area of expertise
1Cancer
Stage IV
Stage III
Stage II
2Prostate Cancer
Stage IV
synaptophysin positive
chromogranin positive
Affiliated Hospitals
Clinical Trials John C. Henegan is currently running
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
More about John C. Henegan
Clinical Trial Related3 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments John C. Henegan has experience with
- Nivolumab
- Docetaxel
- Flutamide
- Prednisone
- Goserelin Acetate
- Nilutamide
Breakdown of trials John C. Henegan has run
Cancer
Prostate Cancer
Bladder Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John C. Henegan specialize in?
John C. Henegan focuses on Cancer and Prostate Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is John C. Henegan currently recruiting for clinical trials?
Yes, John C. Henegan is currently recruiting for 7 clinical trials in Jackson Mississippi. If you're interested in participating, you should apply.
Are there any treatments that John C. Henegan has studied deeply?
Yes, John C. Henegan has studied treatments such as Nivolumab, Docetaxel, Flutamide.
What is the best way to schedule an appointment with John C. Henegan?
Apply for one of the trials that John C. Henegan is conducting.
What is the office address of John C. Henegan?
The office of John C. Henegan is located at: University of Mississippi Medical Center, Jackson, Mississippi 39216 United States. This is the address for their practice at the University of Mississippi Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.